Person with cancer—lung cancer molecular pathology test results, code N[N]
Data Element Attributes
Identifying and definitional attributes | |
Metadata item type: | Data Element |
|---|---|
| Short name: | Molecular test results (lung cancer) |
| Synonymous names: | Molecular pathology results |
| METEOR identifier: | 434682 |
| Registration status: | Health, Standard 08/05/2014 |
| Definition: | The results of a molecular pathology test for genetic and molecular abnormalities in a person with cancer, as represented by a code. |
| Data Element Concept: | Person with cancer—molecular pathology test results |
| Value Domain: | Lung cancer molecular pathology test results code N[N] |
Value domain attributes | ||
Representational attributes | ||
| Representation class: | Code | |
|---|---|---|
| Data type: | Number | |
| Format: | N[N] | |
| Maximum character length: | 2 | |
| Value | Meaning | |
| Permissible values: | 1 | APC - adenomatous polyposis coli |
| 2 | ATM - ataxia telangiectasia mutated | |
| 3 | EGFR - epidermal growth factor receptor | |
| 4 | ERBB4 - v-erb-a erythroblastic leukaemia viral oncogene homolog 4 | |
| 5 | ERCC1 - excision repair cross-complementing rodent repair deficiency, complementation group 1 | |
| 6 | KDR - kinase insert domain receptor | |
| 7 | KRAS - v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | |
| 8 | NF1 - neurofibromin 1 | |
| 9 | PTEN - phosphatase and tensin homolog | |
| 10 | RB1 - retinoblastoma 1 | |
| 11 | RRM1 - ribonucleotide reductase M1 | |
| 12 | STK11 - serine/threonine kinase 11 | |
| 13 | TYMS - thymidylate synthetase | |
| 14 | P53 - tumour protein p53 | |
| 15 | ERBB2 - v-erb-a erythroblastic leukaemia viral oncogene homolog 2 | |
| 16 | EML4-ALK - echinoderm microtubule-associated protein-like 4 – anaplastic lymphoma kinase | |
| 17 | B-RAF - v-Raf murine sarcoma viral oncogene homolog B1 | |
| 18 | ROS - C-Ros Oncogene 1, Receptor Tyrosine Kinase | |
| 19 | MET - Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) | |
| 88 | Other | |
| Supplementary values: | 97 | Not applicable-no abnormalities detected |
| 98 | Unknown whether abnormalities detected | |
| 99 | Abnormalities detected but type not stated/inadequately described | |
Collection and usage attributes | |
| Guide for use: | Each code represents a HUGO Gene Nomenclature Committee (HGNC) assigned unique gene symbol. The full name, location and additional information about each gene can be obtained from their online database at www.genenames.org. Record the code for each genetic or molecular abnormality detected. Molecular pathology testing is usually performed for non-small cell lung cancer (NSCLC) and when the result may influence treatment. |
|---|---|
Source and reference attributes | |
| Submitting organisation: | Cancer Australia |
|---|---|
| Reference documents: | Harris TJR & McCormick F 2010. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 7:251-265 Royal College of Pathologists of Australasia 2010. Lung cancer structured reporting protocol. 1st Edition (Version 1.0). Surry Hills, NSW: Royal College of Pathologists of Australasia HGNC Database, HUGO Gene Nomenclature Committee (HGNC), EMBL Outstation - Hinxton, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK. Viewed 21 June 2011, http://www.genenames.org |
Data element attributes | |
Collection and usage attributes | |
| Guide for use: | Record the results of a molecular pathology test for genetic and molecular abnormalities in a person with cancer. This item should be completed when the data element Molecular pathology indicator is coded as 1, denoting that molecular testing has been performed. Molecular testing is usually performed when the result may influence treatment. For example, somatic mutations in the EGFR gene are associated with favourable outcomes from treatment with gefitinib. |
|---|---|
| Collection methods: | This information should be sought from the patient's pathology report. |
| Comments: | The presence of genetic or molecular abnormalities may be of clinical significance and influence treatment decisions. |
Source and reference attributes | |
| Submitting organisation: | Cancer Australia |
| Reference documents: | Harris TJR & McCormick F 2010. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 7:251-265 |
Relational attributes | |
| Related metadata references: | See also Person with cancer—molecular pathology indicator, yes/no/unknown code N Health, Standard 08/05/2014 See also Person with cancer—molecular pathology test date, DDMMYYYY Health, Standard 08/05/2014 See also Person with cancer—molecular pathology test results, (other) code X[X(19)] Health, Standard 08/05/2014 |
| Implementation in Data Set Specifications: | |